Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AmerisourceBergen elects chairman

Executive Summary

AmerisourceBergen taps Richard Gozon to replace James Mellor as chairman of its board of directors. The appointment is contingent on his re-election as a director during the company's Feb. 9, 2006 annual stockholders meeting. Mellor will retire at the meeting as required by the company's mandatory retirement provisions. A member of the board of directors since the company's creation in August 2001, Gozon previously served as director of AmeriSource Health Corp. for seven years and was exec VP of Weyerhaeuser Corp. from 1994 until his retirement in 2002...

You may also be interested in...



JHL Becomes Eden And Announces Denosumab Progress

Taiwan’s JHL Biotech has rebranded itself as Eden Biologics at the same time as it has announced progress on clinical trials for its denosumab biosimilar candidate.

Australia’s Starpharma Plans To Launch COVID-Killing Nasal Spray In Europe

Starpharma's COVID-busting Viraleze antiviral nasal spray will soon be available across Europe, included the UK. But will it fall foul of local evidence requirements, for example in France, where the country's medicines agency has halted the sale of Pharma & Beauty (P&B) Group's COV-Defense spray until its efficacy against COVID has been confirmed by human-based studies?

Coronavirus Update: Moderna’s Variant-Targeting Vaccine Moves Into Trial, J&J Looks Set For US Authorization

A round up of COVID-19 developments, also including news on the EMA beginning a rolling review of Celltrion's antibody therapy, and progress for Novavax and Moderna in Japan.

Topics

UsernamePublicRestriction

Register

LL1135645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel